2027 related articles for article (PubMed ID: 27510637)
1. Polycystic ovary syndrome.
Azziz R; Carmina E; Chen Z; Dunaif A; Laven JS; Legro RS; Lizneva D; Natterson-Horowtiz B; Teede HJ; Yildiz BO
Nat Rev Dis Primers; 2016 Aug; 2():16057. PubMed ID: 27510637
[TBL] [Abstract][Full Text] [Related]
2. Polycystic ovary syndrome and acne.
Chuan SS; Chang RJ
Skin Therapy Lett; 2010; 15(10):1-4. PubMed ID: 21076799
[TBL] [Abstract][Full Text] [Related]
3. Current concepts of polycystic ovary syndrome.
Rosenfield RL
Baillieres Clin Obstet Gynaecol; 1997 Jun; 11(2):307-33. PubMed ID: 9536213
[TBL] [Abstract][Full Text] [Related]
4. Polycystic ovary syndrome: a review for dermatologists: Part I. Diagnosis and manifestations.
Housman E; Reynolds RV
J Am Acad Dermatol; 2014 Nov; 71(5):847.e1-847.e10; quiz 857-8. PubMed ID: 25437977
[TBL] [Abstract][Full Text] [Related]
5. Polycystic Ovary Syndrome.
Azziz R
Obstet Gynecol; 2018 Aug; 132(2):321-336. PubMed ID: 29995717
[TBL] [Abstract][Full Text] [Related]
6. Polycystic ovary syndrome: a dermatologic approach.
Moura HH; Costa DL; Bagatin E; Sodré CT; Manela-Azulay M
An Bras Dermatol; 2011; 86(1):111-9. PubMed ID: 21437531
[TBL] [Abstract][Full Text] [Related]
7. Androgen excess: Investigations and management.
Lizneva D; Gavrilova-Jordan L; Walker W; Azziz R
Best Pract Res Clin Obstet Gynaecol; 2016 Nov; 37():98-118. PubMed ID: 27387253
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous Findings and Systemic Associations in Women With Polycystic Ovary Syndrome.
Schmidt TH; Khanijow K; Cedars MI; Huddleston H; Pasch L; Wang ET; Lee J; Zane LT; Shinkai K
JAMA Dermatol; 2016 Apr; 152(4):391-8. PubMed ID: 26720591
[TBL] [Abstract][Full Text] [Related]
9. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan.
Teede H; Deeks A; Moran L
BMC Med; 2010 Jun; 8():41. PubMed ID: 20591140
[TBL] [Abstract][Full Text] [Related]
10. Acne severity and the Global Acne Grading System in polycystic ovary syndrome.
Hacivelioglu S; Gungor AN; Gencer M; Uysal A; Hizli D; Koc E; Cosar E
Int J Gynaecol Obstet; 2013 Oct; 123(1):33-6. PubMed ID: 23948280
[TBL] [Abstract][Full Text] [Related]
11. Mild androgen phenotypes.
Carmina E
Best Pract Res Clin Endocrinol Metab; 2006 Jun; 20(2):207-20. PubMed ID: 16772152
[TBL] [Abstract][Full Text] [Related]
12. Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism.
Carmina E; Rosato F; Jannì A; Rizzo M; Longo RA
J Clin Endocrinol Metab; 2006 Jan; 91(1):2-6. PubMed ID: 16263820
[TBL] [Abstract][Full Text] [Related]
13. Metabolic Syndrome: Polycystic Ovary Syndrome.
Mortada R; Williams T
FP Essent; 2015 Aug; 435():30-42. PubMed ID: 26280343
[TBL] [Abstract][Full Text] [Related]
14. Syndromes of hyperandrogenism in women.
Davis S
Aust Fam Physician; 1999 May; 28(5):447-51. PubMed ID: 10376368
[TBL] [Abstract][Full Text] [Related]
15. Polycystic ovary (Stein-Leventhal) syndrome: etiology, complications, and treatment.
Hoyt KL; Schmidt MC
Clin Lab Sci; 2004; 17(3):155-63. PubMed ID: 15314890
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous manifestations of the subtypes of polycystic ovary syndrome in Korean patients.
Hong JS; Kwon HH; Park SY; Jung JY; Yoon JY; Min S; Choi YM; Suh DH
J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):42-7. PubMed ID: 24628922
[TBL] [Abstract][Full Text] [Related]
17. The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited.
Rosenfield RL; Ehrmann DA
Endocr Rev; 2016 Oct; 37(5):467-520. PubMed ID: 27459230
[TBL] [Abstract][Full Text] [Related]
18. The role of obesity in the development of polycystic ovary syndrome.
Motta AB
Curr Pharm Des; 2012; 18(17):2482-91. PubMed ID: 22376149
[TBL] [Abstract][Full Text] [Related]
19. Dermatologic manifestations of polycystic ovary syndrome.
Lee AT; Zane LT
Am J Clin Dermatol; 2007; 8(4):201-19. PubMed ID: 17645376
[TBL] [Abstract][Full Text] [Related]
20. Metabolic dysfunction in polycystic ovary syndrome: Pathogenic role of androgen excess and potential therapeutic strategies.
Sanchez-Garrido MA; Tena-Sempere M
Mol Metab; 2020 May; 35():100937. PubMed ID: 32244180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
